Latest

1 story

Hide weekly roundups

Monday, August 10

Synnovation registers Phase 1 trial of SNV1521 with Revolution Medicines' daraxonrasib

Trial updatedaraxonrasib Revolution Medicines, Inc.

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.